Ozanimod(RPC1063) , 10mMinDMSO , 1306760-87-1

CAS NO.：1306760-87-1

Empirical Formula: C23H24N4O3

Molecular Weight: 404.46

MDL number:

EINECS: 814-246-9

PRODUCT Properties

• Melting point: 134-137°C
• Boiling point: 648.3±65.0 °C(Predicted)
• Density: 1.30±0.1 g/cm3(Predicted)
• storage temp.: -20°C Freezer
• solubility: DMSO (Slightly), Methanol (Slightly)
• form: Solid
• pka: 14.73±0.10(Predicted)
• color: White to Off-White
• InChIKey: XRVDGNKRPOAQTN-FQEVSTJZSA-N
• SMILES: C(#N)C1=CC(C2ON=C(C3=CC=CC4=C3CC[C@@H]4NCCO)N=2)=CC=C1OC(C)C

Description and Uses

Ozanimod is a sphingosine-1-phosphate receptor 1 (S1P₁) and S1P₅ agonist. It induces GTPγS binding in cell membranes expressing human S1P₁ or S1P₅ (EC₅₀s = 0.41 and 11 nM, respectively) but not cell membranes expressing S1P₂ or S1P₃ receptors (EC₅₀s = >10,000 nM for both). Ozanimod (0.2 mg/kg) reduces the number of peripheral lymphocytes in rats. It reduces disease severity and the number of circulating lymphocytes in a mouse model of experimental autoimmune encephalomyelitis (EAE). Ozanimod (0.3 and 1 mg/kg) reduces disease severity and body weight loss in a mouse model of TNBS-induced colitis. Formulations containing ozanimod have been used in the treatment of relapsing multiple sclerosis and ulcerative colitis.

Ozanimod is an agonist that binds to S1P1 and S1P5 receptors. Experiments on rodents revealed that Ozanimod is effective against autoimmune diseases.

Safety

• Symbol(GHS): GHS08
• Signal word: Danger
• Hazard statements: H372
• Precautionary statements: P260-P264-P270-P314-P501